Hims & Hers (HIMS) may have overstepped with the launch of its weight-loss pills following swift blowback from Novo Nordisk (NVO) and U.S. regulators, Michael Erman of Reuters reports. Hims announced plans to offer an oral semaglutide pill for $49, but retreated from this plan two days after U.S. FDA Commissioner Marty Makary warned the offering and similar drugs were “illegal copycats.” Now, it is not clear where the company will look to for long-term growth prospects.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers to acquire Eucalyptus for up to $1.15B
- Is HIMS Stock a Buy Ahead of Earnings? Options Traders Brace for 17% Price Swing
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
- Mixed options sentiment in Hims and Hers Health with shares up 4.78%
- Why Hims & Hers Health (HIMS) Bulls Aren’t Scared of NVO’s Lawsuit